Last reviewed · How we verify
herpes zoster keratitis
Approved treatments
- Ramycin
Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins. - Lotemax · Bausch Health
- Tobi · Novartis
- Fml · AbbVie
- Medrifar · AbbVie
- Cortone
- Lotemax · Tufts Medical Center
- Decadron · Generic (originally Merck)
- Vantobra · Pfizer
- Nebcin · University Hospital, Lille
- Cortef · Generic (originally Merck/Upjohn)
- Flarex · Harrow Health
- Loteprednol Etabonate · Bausch And Lomb
- Cortisol · University of Zurich
- Prelone · Generic (originally Schering)
- prednisolon · Hannover Medical School
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- herpes zoster keratitis patent landscape — cliff calendar, originator estates, attackable patents
- herpes zoster keratitis treatment landscape brief
- herpes zoster keratitis treatment updates RSS
Frequently asked questions about herpes zoster keratitis
What drugs treat herpes zoster keratitis?
Tracked treatments include Ramycin, Lotemax, Tobi, Fml, Medrifar, Cortone, Decadron, Vantobra.
What is the treatment for herpes zoster keratitis?
Standard treatment for herpes zoster keratitis includes Ramycin, Lotemax, Tobi, Fml, Medrifar. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: herpes zoster keratitis patent cliff · herpes zoster keratitis CI report
- Treatment: Ramycin
- Treatment: Lotemax · Bausch Health
- Treatment: Tobi · Novartis
- Treatment: Fml · AbbVie
- Treatment: Medrifar · AbbVie
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing